Trauma promotes trauma-induced coagulopathy, which requires urgent treatment with fixed-ratio transfusions of red blood cells, fresh frozen plasma and platelet concentrates, or goal-directed administration of coagulation factors based on viscoelastic testing. This retrospective observational study compared two time periods before (2005)(2006)(2007) and after (2012)(2013)(2014)) the implementation of changes in trauma management protocols which included: use of goal-directed coagulation management; admission of patients to designated trauma centres; whole-body computed tomography scanning on admission; damage control surgery; permissive hypotension; restrictive fluid resuscitation; and administration of tranexamic acid. The incidence of massive transfusion (≥ 10 units of red blood cells from emergency department arrival until intensive care unit admission) was compared with the predicted incidence according to the trauma associated severe haemorrhage score. All adult (≥ 16 years) trauma patients primarily admitted to the University Hospital Z€ urich with an injury severity score ≥ 16 were included. In 2005-2007, the observed and trauma associated severe haemorrhage score that predicted the incidence of massive transfusion were identical, whereas in 2012-2014 the observed incidence was less than half that predicted (3.7% vs. 7.5%). Compared to 2005-2007, the proportion of patients transfused with red blood cells and fresh frozen plasma was significantly lower in 2012-2014 in both the emergency department (43% vs. 17%; 31% vs. 6%, respectively), and after 24 h (53% vs. 27%; 37% vs. 16%, respectively). The use of tranexamic acid and coagulation factor XIII also increased significantly in the 2012-2014 time period. Implementation of a revised trauma management strategy, which included goal-directed coagulation management, was associated with a reduced incidence of massive transfusion and a reduction in the transfusion of red blood cells and fresh frozen plasma.
Introduction
Trauma is a leading cause of death worldwide [1, 2] . Severe trauma frequently results in trauma-induced coagulopathy [3] , which may increase mortality fourfold [4] and therefore requires urgent treatment [3, 5] . This treatment may consist of administration of red blood cells (RBC), fresh frozen plasma (FFP) and platelet concentrates at a fixed-ratio [6] , or administration of coagulation factors according to an individualised goaldirected algorithm based on viscoelastic tests such as thromboelastography (TEG â ; Hemoscope, Niles, IL, USA) or rotational thromboelastometry (ROTEM â ; TEM International, Munich, Germany) and laboratorybased coagulation tests [2, 7] . Point-of-care coagulation monitoring by viscoelastic testing allows early detection of hyperfibrinolysis, low levels of fibrinogen, low platelet counts and prolonged coagulation initiation in trauma [8, 9] . In addition, point-of-care testing, combined with standard laboratory tests, allows the goal-directed administration of fibrinogen and other coagulation factors and transfusion of allogeneic blood products in order to immediately treat trauma-induced coagulopathy [7, 10] . This new approach to haemostatic resuscitation is one of the key elements in the European Trauma Treatment Guidelines [2] , alongside admission of patients to designated trauma centres [11] , whole-body computed tomography (CT) trauma scans on admission, damage control surgery, permissive hypotension, restrictive fluid resuscitation and administration of tranexamic acid.
Within our institution, which is a designated major trauma centre, an individualised goal-directed transfusion and coagulation algorithm was introduced in 2008 [12] , subsequently revised, and then fully implemented in 2012 [10] . The purpose of this retrospective observational study was to evaluate the impact of changes in the management of trauma patients on the incidence of massive transfusion, administration of allogeneic blood products and mortality in two defined time periods.
Methods
This study was approved by the local ethics committee and adheres to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) recommendations for cohort studies. The study included all adult trauma patients (≥ 16 years) with an injury severity score (ISS) ≥ 16, who were primarily admitted to the University Hospital, Z€ urich, Switzerland. Patients with missing records for initial emergency department treatment, with missing parameters that prevented calculation of the trauma associated severe haemorrhage (TASH) score [13, 14] , and/or secondarily transferred patients were not studied.
In Switzerland, severely injured patients are admitted to one of the 12 level-1 trauma centres by a paramedic team including (most commonly) a designated emergency physician. In the University Hospital Z€ urich, a standardised clinical approach according to leading trauma guidelines is provided in the resuscitation area. The implemented standard operating procedures have included primary whole-body CT scan since 2009 [15] , and a goal-directed transfusion protocol since 2012. Since 2009, other changes in trauma management have also been made, including: early administration of tranexamic acid; restrictive fluid resuscitation (preferably with crystalloid solutions); permissive hypotension; and damage control surgery. Therefore, the 3 years before (2005) (2006) (2007) [16] , and the 3 years after (2012-2014) the introduction and full implementation of these changes were chosen for analysis.
The goal-directed transfusion protocol algorithm is designed to meet the demands of all bleeding patients and includes also massive bleeding in trauma patients (Fig. 1) . The first step is a thorough past medical history on patient factors and medication affecting coagulation (antiplatelet drugs, heparin, oral anticoagulants or history of immune reactions altering coagulation). On emergency room entry, samples for platelet count, factor V and factor XIII activity are sent to the laboratories and a ROTEM analysis is performed. Haematology assays and factor activity measurement are available 24 h a day, within 30 min. ROTEM measurements include EXTEM (tissue factor-activated extrinsic pathway), INTEM (ellagic acid-activated intrinsic pathway), FIBTEM (containing platelet inhibitor cytochalasin D, evaluating the contribution of fibrinogen to clot formation), APTEM (containing aprotinin to inhibit plasmin to evaluate fibrinolysis) and HEPTEM (intrinsic pathway including heparinase to inhibit heparin action). The different treatments for abnormalities identified by point-of-care and laboratory testing are illustrated in Figure 1 .
Patient characteristics, laboratory values, injury patterns, administered blood products, complications and cause of death were extracted from an internal database into a spreadsheet (Excel 2010, Microsoft Corporation, Redmond, WA, USA). Additionally, anaesthestic records of the initial resuscitation in the emergency department (including surgery, if performed) until the admission to the intensive care unit intensive care unit (ICU) were reviewed and the following data were extracted: volume of resuscitation fluids (crystalloid, gelatin and hydroxyl ethyl starch); factor concentrates (fibrinogen, four-factor prothrombin complex concentrate (PCC), coagulation factor XIII, recombinant coagulation factor VIIa); tranexamic acid use; vasopressor use and duration of treatment; and the use of allogeneic blood products such as RBC, FFP and platelet concentrates. Furthermore, the observed and predicted incidence of massive transfusion were compared. To predict the incidence of massive transfusion, the trauma associated severe haemorrhage (TASH) score was used. Figure 1 Most recent version of the transfusion and coagulation algorithm [35] . ACT, activated clotting time; CFT, clot formation time; CT, clotting time; FFP, fresh frozen plasma; HIT, heparininduced thrombocytopenia; INR, international normalised ratio; IU/U, international units; i.v., intravenous; MCF, maximum clot firmness; PT, prothrombin time; RBC, red blood cells; rFVIIa, recombinant-activated factor VII; TT, thrombin time.
The TASH score defines massive transfusion as the transfusion of ≥ 10 units of RBC between admission to the emergency department and admission to the ICU, and has been validated for the prediction of massive transfusion [13] . To calculate the TASH score, patient gender, initial systolic blood pressure, heart rate, haemoglobin, base excess, positive focused assessment with sonography for trauma (FAST) for intra-abdominal fluid, clinically unstable pelvis and open or dislocated femur fracture are considered. The overall score varies from zero to 28 points corresponding to an increasing probability for massive transfusion using the following calculation: probability of massive transfusion = 1/ [1 + exp(5.4-0.3 9 TASH)] [13] . The injury severity score (ISS) was used to describe and classify severity of injury [17] .
The primary outcome measures were the difference in observed vs. TASH-predicted incidence of massive transfusion and the consumption of allogeneic blood products and coagulation factors in the two cohorts (2005-2007 and 2012-2014) . Mortality rates in the two time periods was assessed as a secondary outcome measure.
Chi-squared and Fisher's exact tests were used to compare categorical data and the Mann-Whitney Utest to compare numerical data. Multiple logistic regression analyses were performed for massive transfusion rates, in-hospital and 24-h mortality, proportion of patients receiving RBC, FFP and platelet transfusions (in the emergency department and after 24 h). Predictor variables were: the two time periods; TASH score; patient age; GCS on scene; ISS; penetrating trauma; and the following values on admission: platelet count; fibrinogen; international normalised ratio (INR); and temperature. Odds ratios (OR), 95% CI and p values were calculated. The model fit was assessed using the Hosmer-Lemeshow test. All statistical analyses were performed using SPSS version 22 (IBM Corp., Armonk, NY, USA). A p value of ≤ 0.01 was considered statistically significant.
Results
After exclusions, 731 complete records were available for analysis: 323 patients in 2005-2007 and 408 in [2012] [2013] [2014] (Fig. 2) . Baseline patient characteristics are shown in Table 1 . The 2005-2007 cohort were younger, but had a higher ISS, greater incidence of penetrating trauma and lower GCS compared with 2012-2014. Heart rate, systolic blood pressure, haemoglobin and base excess on admission were similar in both periods. The time from emergency department admission until admission to the ICU was significantly shorter in the 2012-2014 cohort. Adherence to the coagulation algorithm was good, as in transfused patients the mean (SD) haemoglobin value during emergency department treatment was 77 (13) g.l À1 in the 2012-2014 period, and therefore well within the targeted region of 70-80 g.l
À1
. Figure 2 Flow chart of patient inclusion and exclusion criteria. TASH, trauma-associated severe haemorrhage.
The incidence of massive transfusion in 2005-2007 was 12.4% and in line with the 12.1% TASH score prediction. The observed incidence of massive transfusion in the 2012-2014 cohort was significantly reduced and was around 50% of that predicted by the TASH score (3.7% observed vs. 7.5% predicted). After correction for the altered patient and trauma epidemiology, the probability of massive transfusion was significantly reduced in the 2012-2014 cohort (adjusted OR 0.16, 95%CI 0.06-0.42) ( Table 2 ). Transfusion of RBC and FFP (both in the emergency department and in the first 24 h) were also lower in 2012-2014 group, although platelet administration did not differ between the time periods (Tables 2 and 3 ).
The use of tranexamic acid and coagulation factor XIII increased significantly in 2012-2014, whereas fibrinogen administration remained unchanged (Table 3) . The mean overall doses of PCC and fibrinogen did not change and no patient in the 2012-2014 group received recombinant coagulation factor VIIa. The overall use of resuscitation fluids was reduced in the 2012-2014 cohort, particularly the use of starch, although the use of gelatin did increase (Table 3) .
Mortality at 24 h and overall in-hospital mortality was significantly lower in the 2012-2014 cohort. Length of ICU stay and days of ventilator support were also reduced in the 2012-2014 group but overall length of hospital stay remained similar to 2005-2007 (Table 2) .
Discussion
Following the implementation of goal-directed coagulation management and a change in other aspects of trauma management, the incidence of massive transfusion after trauma was reduced by 50% compared with that predicted by the TASH score.
In the 2012-2014 cohort, patients were older and had a lower ISS; this is in accordance with data from the German Trauma Register, which have shown a linear increase in patient age of 0.8 years per year, with a small decrease in ISS of 0.3 per year [18] . The shorter time of initial emergency department treatment until ICU admission in the 2012-2014 group of patients is in accordance with the concept of damage control surgery and a whole-body CT-based imaging algorithm for multiple trauma patients [15] . The reduced incidence of massive transfusion, allogeneic blood product transfusion and hospital mortality (all corrected for the change in patient and trauma epidemiology) is remarkable, since Sierink and colleagues recently showed that an initial whole-body CT alone compared with a standard work up does not reduce transfusion requirements [19] . Coagulation assays showed that the patients in 2012-2014 cohort were more severely coagulopathic, as evidenced by a significantly higher INR and significantly lower platelet count on admission. The exact reason for this remains unclear, although the fact that this cohort was on average 10 years older, might be one important factor.
Scores like TASH were developed to identify trauma patients at risk of massive transfusion based on data readily available on admission to the trauma centre, in order to justify an initiation of a massive transfusion protocol, even before coagulation measurements are available [20] [21] [22] . A goal-directed strategy implies monitoring by routine haematology, coagulation assays and viscoelastic tests before treatment, to allow identification of the significant number of patients who do not require RBC transfusion [7] . Red blood cell transfusion in the setting of goal-directed treatment is only initiated according to evidencebased low transfusion triggers, as RBC and FFP transfusions lead to dilution of coagulation factors since RBC do not contain any coagulation factors and fibrinogen levels in FFP are low and highly variable [23] . A low fibrinogen level can be detected within 10 min using viscoelastic tests [24] and targeted fibrinogen concentrate substitution reduces the need for FFP and RBC transfusion in trauma patients [24] . The incidence and dose of fibrinogen administration did not change between the two time periods, which is due to goal-directed, instead of empirical use of fibrinogen concentrate, as shown by Weber et al. [25] .
Coagulation factor XIII stabilises the fibrin clot in vitro and reduces postoperative bleeding in cardiac surgery [26, 27] . In vitro it is able to at least partly overcome coagulopathy and platelet dysfunction caused by colloidal resuscitation fluid [28, 29] . Factor XIII measurement and administration was Odds ratio (OR) adjusted for trauma-associated severe haemorrhage TASH score (which includes sex, initial systolic blood pressure, heart rate, haemoglobin, base excess, positive focused assessment with sonography for trauma scan for intra-abdominal fluid, clinically unstable pelvis and open or dislocated femur fracture), patient age, initial GCS, injury severity score, platelet count on admission, fibrinogen on admission, INR on admission, penetrating trauma, temperature on admission. RBC, red blood cells; ED, emergency department; FFP, fresh frozen plasma; ICU, intensive care unit; INR, international normalised ratio.
implemented to facilitate avoidance of FFP, formerly the only source of coagulation factor XIII. The use of starch solutions disappeared almost completely in the 2012-2014 group and were only partially substituted by gelatin use, leading to a significant decrease in overall colloid use. This may have preserved platelet function and thus be partly responsible for the observed reduction in transfusion requirements. However, significant volumes of colloid resuscitation fluids were infused in both time periods and the effects of this on coagulation cannot be qualified or quantified in this study.
Since the CRASH-2 trial was published in 2011 [30] , the use of tranexamic acid in trauma has increased. The European Trauma Treatment Guidelines recommend the early empirical administration of tranexamic acid to bleeding trauma patients or patients at risk of significant haemorrhage [2] . The rate of tranexamic acid use in the 2012-2014 cohort may be an underestimate, because in Switzerland pre-hospital tranexamic acid administration was initiated during this time period. In such patients, no additional tranexamic acid was given and therefore documented in the emergency department. The impact of tranexamic acid on overall and bleeding-associated mortality has been shown in the CRASH-2 trial, but it should be noted that its use had no impact on the quantity of blood products transfused [30] .
The incidence of platelet concentrate transfusion did not change between the two time periods. An increased use of mono-and dual-platelet inhibition in the older population in the 2012-2014 cohort may account for that phenomenon [31] . The use of PCC did not change over time. The optimal dose of PCC in coagulopathic trauma patients with normal fibrinogen plasma levels is unclear. Therefore, the European Trauma Treatment Guidelines recommend PCC administration only to bleeding patients with documented evidence of delayed coagulation initiation (goal-directed approach) and to trauma patients who are anticoagulated with vitamin K antagonists [2] . Raw and adjusted 24 h and in-hospital mortality decreased significantly in the 2012-2014 time period; although the study was not powered for this end-point, this suggests non-inferiority of the novel approach. In a prospective randomised study of patients expected to need massive transfusion, a fixed-ratio transfusion protocol (1:1:1, RBC:FFP:platelets) was compared with a laboratory result-guided transfusion strategy [32] . Allcause 28-day mortality was higher in the fixed-ratio group (13/40 vs. 25/32), although these data were presented only as safety data and the study was not powered for this outcome. The PROPPR randomised clinical trial compared two fixed-ratio transfusions (FFP:platelets:RBC, 1:1:1 vs. 1:1:2) in trauma patients [6] . Although not directly comparable because of different trauma and patient epidemiology, the observed 24-h (12.7% and 17.0%) and 30-day mortality (22.4% and 26.1%) are similar to the results seen in our 2012-2014 cohort. This suggests that a goal-directed regimen was not inferior to a fixed-ratio transfusion strategy. Gonzales and colleagues compared a massive transfusion protocol based on goal-directed viscoelastic assays (thromboelastography) with a protocol with only conventional coagulation assays [33] . Survival in the thromboelastography group was significantly higher, and FFP and platelet transfusions significantly lower. Nardi et al. reported an improved in-hospital (20% vs. 13.5%) and 24-h mortality (6.15% vs. 3.12%) after the introduction of a fibrinogen-based early coagulation support algorithm [34] . The study, however, was not sufficiently powered to demonstrate statistically significant differences in these end points.
Our study has several limitations. Data analyses were performed retrospectively and therefore a causal relationship for the outcome variables cannot be inferred. However, data quality are high, as all the emergency department and the 24-h measurement data have been collected independently and cross-checked. The documentation of all parameters followed Good Clinical Practice guidelines. Between the two study periods, multiple changes were introduced into clinical practice and it is not possible to determine the individual impact of each one. Beside the coagulation management, diagnostic, surgical, intensive care and hospital care management also changed. Performing a randomised, controlled, double-blinded study comparing a fixed-ratio regimen with a goal-directed regimen based on coagulation factors and point-of-care diagnostic testing would be difficult, as these two approaches cannot be blinded and conducted in parallel, as the main approach is completely different. Therefore, comparing two time periods and showing a reduction in the transfusion of allogeneic blood products may be considered a pragmatic approach.
In conclusion, the implementation of goal-directed coagulation management in tandem with a change in surgical management was associated with a reduced incidence of massive transfusion and transfusion of RBC and FFP, without an increase in mortality rates.
